PT - JOURNAL ARTICLE AU - Minakshi Dhar AU - Kartik Mittal AU - Ashwin Parchani AU - Manu Sharma AU - Yogesh Bahurupi AU - Sanjay Kalra AU - Nowneet K Bhat TI - Adjuvant Testosterone Therapy in Chronic Heart Failure (ATTIC) – A Randomised Open-Label Trial AID - 10.1101/2021.09.07.21262892 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.07.21262892 4099 - http://medrxiv.org/content/early/2021/10/11/2021.09.07.21262892.short 4100 - http://medrxiv.org/content/early/2021/10/11/2021.09.07.21262892.full AB - Introduction Heart failure is a major contributor to morbidity and mortality in the geriatric population, with no promising therapy currently available with considerable benefit. Testosterone therapy is an emerging viable treatment option given its beneficial effects, including improving cardiac functional capacity, alleviating symptoms, and low cost, amongst others.Methods We have planned an open-label, parallel design, 1:1 randomized controlled trial which aims to recruit 160 adult males above the age of 60 diagnosed with chronic stable heart failure fulfilling the eligibility criteria. The participants will be randomized into two groups of 80 each. Both groups will receive standard recommended treatment regime of chronic stable heart failure and intervention arm participants will receive additional testosterone gel. All participants will be assessed at baseline, 4 weeks, 6 weeks and 12 weeks. The primary endpoints will assess the difference in functional capacity, frailty and quality of life at 3 months compared to baseline. The secondary endpoints will include the mean change from baseline at 3 months in cardiac remodelling using echocardiography, serum brain natriuretic peptide levels, the incidence of adverse drug reaction.Statistical Analysis The data will be analysed with the help of SPSS software. Primary objectives of change in 6MWT, Frailty index and quality of life will be analysed using the student t-test. The statistical significance will be defined as p-value <0.05 and taking confidence level as 95%.Ethical clearance Institutional Ethics Committee clearance taken via letter no AIIMS/IEC/20/847, dated 21/11/2020Competing Interest StatementThe authors have declared no competing interest.Clinical Trial(CTRI) - REF/2020/12/030292Funding StatementThe study will be funded by the Institutional research GrantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Central Drugs Standard control Organization (DSCO), directorate general of health Services, Government of India Reg No: ECR/736/Inst/UK/2015/RR-18 issued under Rule 122Dd of the Drugs & Cosmetics Rules 1945I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll Data will be made available